Lunai Bioworks (LNAI) Gross Margin (2013 - 2026)

Lunai Bioworks (LNAI) recorded quarterly Gross Margin of 100.0% in Q1 2026, up 14.55% quarter-over-quarter from 87.3% in Q2 2016.

Lunai Bioworks (LNAI) Gross Margin (2013 - 2026) Analysis & Trends

Lunai Bioworks' Gross Margin history runs 3 years deep, the most recent figure standing at 100.0% for Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 100.0%; the TTM figure through Mar 2026 stood at 174.45% (changed N/A YoY), while the FY2016 annual figure was 87.67%, changed N/A from the prior year.
Gross Margin was 100.0% for Q1 2026 at Lunai Bioworks, up from 87.3% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2026 to a low of 100.0% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	79.04%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	86.85%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Lunai Bioworks	95.85 Mn	92.70 Mn	20,942.00	100.00%

Download Data